Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068105 · ClinicalTrials.gov registry record · Phase 1
A Study of ALKS 5461 in Healthy Volunteers
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT02068105: Completed Phase 1 study, sponsored by Alkermes.
NCT02068105 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02068105, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is a study to test the safety of ALKS 5461 in healthy adults.
Primary Outcome
The parameters for determining the bioavailability include Cmax, AUC last, and AUC(0-infinity).
Interventions
- DRUG Placebo
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT02068105 record still lists
NCT02068105 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02068105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02068105 about?
NCT02068105 is a clinical study titled "A Study of ALKS 5461 in Healthy Volunteers". This is a study to test the safety of ALKS 5461 in healthy adults.
What is the current status of trial NCT02068105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2014-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02068105?
The interventions under investigation include: Placebo (DRUG), ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02068105?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02068105's enrollment target sits among peer trials
104 536th of 2000 higher than 1,460 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia